Researchers from Kashan University of Medical Sciences Report on Findings in Parkinson's Disease (The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A ...)
By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Parkinson's disease have been published. According to news reporting originating in Kashan, Iran, by NewsRx journalists, research stated, "The current research was performed to evaluate the effects of omega-3 fatty acids and vitamin E co-supplementation on clinical signs and metabolic status in people with Parkinson's disease (PD). This randomized double-blind placebo-controlled clinical trial was conducted in 60 patients with PD."
Financial support for this research came from Vice-chancellor for Research, KUMS, and Iran (see also Parkinson's Disease).
The news reporters obtained a quote from the research from the Kashan University of Medical Sciences, "Participants were randomly assigned into two groups to receive either 1000 mg omega-3 fatty acids from flaxseed oil plus 400 IU vitamin E supplements (n = 30) or placebo (n = 30) for 12 weeks. Unified Parkinson's disease rating stage (UPDRS) were recorded at baseline and the after 3-month intervention. After 12 weeks' intervention, compared with the placebo, omega-3 fatty acids and vitamin E co-supplementation led to a significant improve in UPDRS (-3.3 +/- 10.0 vs. +4.4 +/- 14.9, P = 0.02). Furthermore, co-supplementation decreased high-sensitivity C-reactive protein (hs-CRP) (-0.3 +/- 0.6 vs. +0.3 +/- 03 mu g/mL, P< 0.001), and increased total antioxidant capacity (TAC) (+65.2 +/- 68.7 vs. +16 +/- 52.4 mu mol/L, P = 0.003) and glutathione (GSH) concentrations (+41.4 +/- 80.6 vs. -19.6 +/- 55.9 mu mol/L, P = 0.001) compared with the placebo. Additionally, co-supplementation meaningfully decreased insulin (-2.1 +/- 4.9 vs. +1.4 +/- 6.2 mu IU/mL, P = 0.01), homeostasis model of assessment-estimated insulin resistance (-0.7 +/- 1.8 vs.+0.3 +/- 1.6, P = 0.02) and Beta cell function (-5.9 +/- 13.9 vs. +5.7 +/- 25.5, P = 0.03), and increased quantitative insulin sensitivity check index (+0.009 +/- 0.02 vs. -0.006 +/- 0.03, P = 0.03) compared with the placebo."
According to the news reporters, the research concluded: "Overall, our study demonstrated that omega-3 fatty acids and vitamin E co-supplementation in people with PD had favorable effects on UPDRS, hs-CRP, TAC, GSH and markers of insulin metabolism."
For more information on this research see: The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Neurochemistry International, 2017;108():183-189. Neurochemistry International can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Neurochemistry International - www.journals.elsevier.com/neurochemistry-international/)
Our news correspondents report that additional information may be obtained by contacting Z. Asemi, Kashan Univ Med Sci, Res Center Biochem & Nutr Metab Dis, Kashan, Iran. Additional authors for this research include O.R. Tamtaji, E. Dadgostar, R.D. Kakhaki, F. Bahmani, J. Abolhassani, M.H. Aarabi, E. Kouchaki, M.R. Memarzadeh and M. Taghizadeh.
Keywords for this news article include: Kashan, Iran, Asia, Central Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions, Basal Ganglia Diseases and Conditions, Brain Diseases and Conditions, Clinical Trials and Studies, Parkinsonian Disorders, Parkinson's Disease, Movement Disorders, Clinical Research, Peptide Proteins, Peptide Hormones, Proinsulin, Vitamin E, Kashan University of Medical Sciences.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC